



**Santhera Pharmaceuticals Holding AG**  
Hammerstrasse 49  
CH-4410 Liestal / Switzerland  
Phone +41 61 906 89 50  
Fax +41 61 906 89 51  
[www.santhera.com](http://www.santhera.com)

## **Santhera to Raise Capital Through Sale of Newly Created Shares**

**Liestal, Switzerland, July 31, 2015 – Santhera Pharmaceuticals (SIX: SANN) announces the intent to sell up to 300,000 registered shares of newly created treasury shares (representing 6.03% of the company's total outstanding share capital). The proceeds will be used to finance the commercial launch of Raxone® in Leber's Hereditary Optic Neuropathy (LHON) in Europe.**

The shares available-for-sale with a par value of CHF 1.00 will be issued from the Company's conditional capital. The Company has mandated Kepler Chevreux as independent broker to sell the shares to institutional investors and in the open market starting from August 3, 2015.

### **About Santhera**

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Raxone®/Catena® as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and primary progressive Multiple Sclerosis (ppMS) and omigapil for Congenital Muscular Dystrophy (CMD), all areas of high unmet medical need. In June 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorization in Europe for Raxone® for the treatment of LHON. For further information, please visit the Company's website [www.santhera.com](http://www.santhera.com).

*Raxone® and Catena® are trademarks of Santhera Pharmaceuticals.*

### **For further information, contact:**

Thomas Meier, PhD, Chief Executive Officer  
Phone +41 61 906 89 64  
[thomas.meier@santhera.com](mailto:thomas.meier@santhera.com)

Christoph Rentsch, Chief Financial Officer  
Phone +41 61 906 89 65  
[christoph.rentsch@santhera.com](mailto:christoph.rentsch@santhera.com)

### **US investor contact:**

Hans Vitzthum, LifeSci Advisors, LLC  
Phone +1 857 272 617  
[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)

### **US Public Relations contact:**

Deanne Eagle, Planet Communications  
Phone +1 917 837 5866  
[deanne@planetcommunications.nyc](mailto:deanne@planetcommunications.nyc)

## **Santhera to Raise Capital Through Sale of Newly Created Shares**

July 31, 2015 / Page 2 of 2

### **Disclaimer / Forward-looking statements**

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #